00:32:14 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2023-08-25 Kvartalsrapport 2023-Q2
2023-04-28 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma 2022
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-04-29 Ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Kvartalsrapport 2020-Q2
2020-04-06 Ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-04-08 Ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma 2019
2018-08-30 Kvartalsrapport 2018-Q2
2018-03-29 Årsstämma 2018

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamma inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.
2022-03-17 14:30:00

BBS-Bioactive Bone Substitutes Plc, Company Release, March 17th, 2022 at 3.30 pm

BBS-Bioactive Bone Substitutes Plc: Decisions of the Extraordinary General Meeting 2022

BBS-Bioactive Bone Substitutes Plc’s Extraordinary General Meeting (EGM) was held today, on Thursday 17th March 2022 from 2:00 pm in Oulu.

Authorizations

The Extraordinary General Meeting decided to authorize the Board of Directors to decide in one or more instalments on share issues and on the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act as follows:

  • The maximum number of shares to be issued pursuant to the authorization shall not exceed 6,000,000 shares.
  • The Board of Directors decides on all terms and conditions for issuing shares, options and other special rights entitling to shares. Share issues and the issuance of option rights and other special rights entitling to shares may take place in deviation from the shareholders' pre-emptive subscription right (directed issue) if there is a weighty financial reason for the company to do so. The authorization applies to the transfer of both new shares and own shares held by the company.
  • In the company's share issue, shares may be transferred either in exchange for payment or free of charge. A directed share issue may be free of charge only if there is a particularly significant financial reason for the company and it is in the interests of all its shareholders.
  • The authorization is valid until June 30th, 2023, and it revokes the authorization granted by the Annual General Meeting on April 28th, 2021, as it enters into force.

The minutes of the EGM will be available on the Company’s website www.bbsartebone.fi no later than March 31st 2022.

For more information:

Ilkka Kangasniemi, CEO, puh. +35840 7080307, e-mail: ilkka.kangasniemi@bbs-artebone.fi
Liisa Hukka, CFO, puh. +35840 0611038, e-mail: liisa.hukka@bbs-artebone.fi

Certified Advisor: Nordic Certified Adviser AB, p. +46 70 551 67 29, info@certifiedadviser.se

DISTRIBUTION:
Nasdaq Helsinki Oy Nasdaq Stockholm AB
Key media
www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes Plc is the health technology company operating since 2003. Before that there was a background of seven years of product development in the University of Oulu. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are characterized by top expertise, innovativeness and dedicated and committed employees. The ARTEBONE ®product is ready and the application process for the CE-mark has been initiated. BBS is the company having its headquarters in Oulu. We have our own production plant located in Reisjärvi and it is approved by FIMEA. More information: www.bbs-artebone.fi